US$ 23.71
when will tirzepatide get fda approval is FDA-approved for weight management, with clinical trials showing average weight loss of 15–22.5% over 72 weeks. It's a prescription-only therapy, meaning it's not for everyone, and it works by acting The US-FDA has approved Tirzepatide
Description
Novo Nordisks WEGOVY (semaglutide) and Eli Lillys ZEPBOUND (tirzepatide) are reshaping the anti-obesity drug marketbut which powerhouse will claim the top spot in this high-stakes race

Retatrutide is not yet FDA-approved, so direct comparison in real-world use is not yet possible

That is approaching tirzepatide territory, particularly considering the shorter trial duration

Why Trial Results Should Not Be Compared Too Casually Patients often see headlines comparing weight-loss percentages across different medications

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown superior efficacy in glycemic control, weight loss and cardiometabolic outcomes compared to GLP-1 agonists alone

5mg/mL concentration dosage chart The 5mg/mL concentration is the most dilute common formulation
